In 2020, Shi et al. prepared carrier‐free hybrid nanospheres via Fe3+‐coordinated self‐assembly to integrate Fe3+, aggregation‐induced emission photosensitizer (TPEDCC), and the Bcl‐2 inhibitor (sabutoclax) into a single nanoplatform (Figure 9a).[50] After the nanospheres were intravenously injected into the tumor‐bearing mice, a strong in vivo FL signal was discerned at the tumor site, which indicated that the nanospheres were accumulated in the targeted tumors, and the signal intensity increased to a maximum value after 4 h, which was maintained at 6 h (Figure 9b). The gene discussed is BCL2; the disease is neoplasm.